[A critical review of available tools for evaluating memory enhancers in Alzheimer's disease].

The study reviews critically the neuropsychological measurement tools available to assess the efficacy of potential memory enhancers in patients with Alzheimer's disease (AD). A review of some concepts concerning the characteristics of memory impairment in AD patients and of problems related to the selection of a study population provides a framework for this analysis. The tools available for efficacy evaluations are then classified according to their conceptual and formal characteristics: psychometric tests, rating scales and clinician global assessment tools.

Predictors of life satisfaction amongst retired people in Paris.

Background: The objective of the present study was to examine predictors of life satisfaction in a survey of retired men and women living in the Paris Metropolitan area.

Methods: In all 627 subjects took part in the first phase of the survey (1982-1983, T1), and 464 in the follow-up phase (1987-1988, T2) during which life satisfaction was evaluated, using the Life Satisfaction Index A (LSIA). Possible predictors were explored among the factors characterizing subjects at T1 and among those related to their occupational history.

[Verbal fluency and EEG coherence in Alzheimer's disease].

EEG coherence of 16 derivations and a verbal fluency test were evaluated on 25 ambulatory patients suffering from Alzheimer's disease (age: 74 +/- 5.7). The aim of the study was to analyze coherence rate variations from different cortical areas in relation to the performance in the test.

[The significance of quantified EEG in Alzheimer's disease. Changes induced by piracetam].

One study was performed in 12 patients with presenile Alzheimer's disease (group I), the other one in 16 patients with mild senile dementia of Alzheimer type (group II). In each study, patients were divided into two randomized parallel groups, one receiving placebo, the other piracetam (9 g daily in group I piracetam and 2.4 g daily in group II piracetam) during three months, piracetam induced a decrease in EEG power on the 2-6 Hz range (group I piracetam), 3-5 Hz and 7 Hz (group II piracetam) and an increase of EEG power in the 9-11 Hz range (group I piracetam) and in the 10 Hz and 13 Hz frequencies (group II piracetam).